| 11 |
Design, synthesis, and structural elucidation of ethyl 2-amino-5-oxo-4-aryl-4H-pyrano[3,2-c] quinoline-3-carboxylates as dual EGFR/HER-2 inhibitors endowed with antiproliferative activity |
2025 |
| 12 |
Design, synthesis, antimalarial activity, and in-silico studies of new benzimidazole/pyridine hybrids as dihydrofolate reductase inhibitors |
2025 |
| 13 |
Design, synthesis, antiproliferative activity, and molecular dynamics simulation of pyrazolinebased derivatives as dual EGFR and HER-2 inhibitors |
2025 |
| 14 |
Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR/HER-2 inhibitors |
2025 |
| 15 |
Design, synthesis, apoptotic antiproliferative, and antioxidant activities of a new series of 2-mercaptobenzimidazole/3-cyanopyridin-2-one hybrids as dual EGFR/BRAFV600E inhibitors |
2025 |
| 16 |
Design, Synthesis, Biological Evaluation, and In Silico Studies of New Nitazoxanide Derivatives: Toward Broad‐Spectrum Antimicrobial Agents |
2025 |
| 17 |
Discovery of a novel 1H-pyrazole -[3,4-d] pyrimidine inhibitor based on phenotypic screening for esophageal cancer: Weak cardiotoxicity |
2025 |
| 18 |
Exploring the antitrypanosomal potential of rosemary root endophytic fungi with metabolomic profiling and molecular docking insights |
2025 |
| 19 |
Further insights into the multitarget anticancer activity of tetrahydrocarbazole-1-amine/5-arylidene-4-thiazolinone based hybrids |
2025 |
| 20 |
N-substituted-5-[(2,5-dihydroxybenzyl)amino]salicylamides as lavendustin analogs: antiproliferative activity, COMPARE analyses, mechanistic, docking, ADMET and toxicity studies |
2025 |
